Valeant Slips After JPMorgan Says Sell On Stretched Valuation, High Expectations
December 14, 2017 at 16:16 PM EST
Shares of Valeant Pharmaceuticals are sliding after JPMorgan analyst Chris Schott downgraded the stock to Underweight.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.